Literature DB >> 33958327

Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.

Marlou T H F Janssen1, Sofia Ramiro2,3, Robert B M Landewé3,4, César Magro-Checa3, Rémy L M Mostard5.   

Abstract

Entities:  

Keywords:  Covid-19; glucocorticoids; inflammation

Year:  2021        PMID： 33958327     DOI： 10.1136/annrheumdis-2021-220040

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

Review 1.  Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.

Authors:  Abdullahi Rabiu Abubakar; Rahnuma Ahmad; Adekunle Babajide Rowaiye; Sayeeda Rahman; Katia Iskandar; Siddhartha Dutta; Angus Nnamdi Oli; Sameer Dhingra; Maryam Abba Tor; Ayukafangha Etando; Santosh Kumar; Mohammed Irfan; Marshall Gowere; Kona Chowdhury; Farhana Akter; Dilshad Jahan; Natalie Schellack; Mainul Haque
Journal:  Life (Basel)       Date:  2022-03-25

2.  Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study.

Authors:  Marlou Thf Janssen; Sofia Ramiro; Rémy Lm Mostard; Cesar Magro-Checa; Robert Bm Landewé
Journal:  RMD Open       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.